MicroRNAs in Lung Cancer

Overview

Journal World J Methodol

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2014 Oct 22

PMID 25332906

Citations 32

Authors

Pooja Joshi

Justin Middleton

Young-Jun Jeon

Michela Garofalo

Affiliations

Soon will be listed here.

Abstract

MicroRNAs have become recognized as key players in the development of cancer. They are a family of small non-coding RNAs that can negatively regulate the expression of cancer-related genes by sequence-selective targeting of mRNAs, leading to either mRNA degradation or translational repression. Lung cancer is the leading cause of cancer-related death worldwide with a substantially low survival rate. MicroRNAs have been confirmed to play roles in lung cancer development, epithelial-mesenchymal transition and response to therapy. They are also being studied for their future use as diagnostic and prognostic biomarkers and as potential therapeutic targets. In this review we focus on the role of dysregulated microRNA expression in lung tumorigenesis. We also discuss the role of microRNAs in therapeutic resistance and as biomarkers. We further look into the progress made and challenges remaining in using microRNAs for therapy in lung cancer.

Citing Articles

Xue P, Zhang G, Zhang H, Cui S, Zhang L, Yu T J Cell Mol Med. 2022; 26(21):5439-5451.

PMID: 36181289 PMC: 9639052. DOI: 10.1111/jcmm.17566.

Identification by MicroRNA Analysis of Environmental Risk Factors Bearing Pathogenic Relevance in Non-Smoker Lung Cancer.

Izzotti A, Vargas G, Pulliero A, Coco S, Colarossi C, Blanco G J Pers Med. 2021; 11(7).

PMID: 34357133 PMC: 8307636. DOI: 10.3390/jpm11070666.

MicroRNA-3613-5p Promotes Lung Adenocarcinoma Cell Proliferation through a RELA and AKT/MAPK Positive Feedback Loop.

He T, Shen H, Wang S, Wang Y, He Z, Zhu L Mol Ther Nucleic Acids. 2020; 22:572-583.

PMID: 33230458 PMC: 7562961. DOI: 10.1016/j.omtn.2020.09.024.

MicroRNA-425-5p Inhibits Lung Cancer Cell Growth and by Downregulating TFIIB-Related Factor 2.

Yu X, Zheng H, Sun R, Qian X, Jiang P, Yang B Technol Cancer Res Treat. 2020; 19:1533033819901115.

PMID: 31964245 PMC: 6978817. DOI: 10.1177/1533033819901115.

Aberrant MicroRNAomics in Pulmonary Complications: Implications in Lung Health and Diseases.

Kumar Dutta R, Chinnapaiyan S, Unwalla H Mol Ther Nucleic Acids. 2019; 18:413-431.

PMID: 31655261 PMC: 6831837. DOI: 10.1016/j.omtn.2019.09.007.

References

Borchert G, Lanier W, Davidson B . RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006; 13(12):1097-101. DOI: 10.1038/nsmb1167. View

Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y, Ngankeu A . EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2011; 18(1):74-82. PMC: 3467100. DOI: 10.1038/nm.2577. View

Grosso S, Doyen J, Parks S, Bertero T, Paye A, Cardinaud B . MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis. 2013; 4:e544. PMC: 3615727. DOI: 10.1038/cddis.2013.71. View

Zhang S, Zhang C, Li Y, Wang P, Yue Z, Xie S . miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Biomed Pharmacother. 2011; 65(6):436-42. DOI: 10.1016/j.biopha.2011.04.010. View

Crawford M, Brawner E, Batte K, Yu L, Hunter M, Otterson G . MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008; 373(4):607-12. DOI: 10.1016/j.bbrc.2008.06.090. View

Akbas F, Coskunpinar E, Aynaci E, Oltulu Y, Yildiz P . Analysis of serum micro-RNAs as potential biomarker in chronic obstructive pulmonary disease. Exp Lung Res. 2012; 38(6):286-94. DOI: 10.3109/01902148.2012.689088. View

Holleman A, Chung I, Olsen R, Kwak B, Mizokami A, Saijo N . miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene. 2011; 30(43):4386-98. PMC: 3572709. DOI: 10.1038/onc.2011.148. View

Unoki M, Nishidate T, Nakamura Y . ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 2004; 23(46):7601-10. DOI: 10.1038/sj.onc.1208053. View

Zhong Z, Dong Z, Yang L, Gong Z . miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer. J Cancer Res Clin Oncol. 2012; 138(10):1781-8. DOI: 10.1007/s00432-012-1287-y. View

10.

Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti G, Papotti M . Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 2010; 8(9):1207-16. DOI: 10.1158/1541-7786.MCR-10-0052. View

11.

Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J . miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 2011; 69(3):723-31. DOI: 10.1007/s00280-011-1752-3. View

12.

Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam S, Lee L . MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm. 2011; 8(4):1381-9. PMC: 4136514. DOI: 10.1021/mp2002076. View

13.

Li F, Sethi G . Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 2010; 1805(2):167-80. DOI: 10.1016/j.bbcan.2010.01.002. View

14.

Lin H, Chiang C, Hung W . STAT3 upregulates miR-92a to inhibit RECK expression and to promote invasiveness of lung cancer cells. Br J Cancer. 2013; 109(3):731-8. PMC: 3738132. DOI: 10.1038/bjc.2013.349. View

15.

He X, Duan C, Chen J, Ou-Yang X, Zhang Z, Li C . Let-7a elevates p21(WAF1) levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells. FEBS Lett. 2009; 583(21):3501-7. DOI: 10.1016/j.febslet.2009.10.007. View

16.

Golsteyn R, Mundt K, Fry A, Nigg E . Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol. 1995; 129(6):1617-28. PMC: 2291169. DOI: 10.1083/jcb.129.6.1617. View

17.

Shen J, Liu Z, Todd N, Zhang H, Liao J, Yu L . Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011; 11:374. PMC: 3175224. DOI: 10.1186/1471-2407-11-374. View

18.

Chen J, Wang B, Tang J . Clinical significance of microRNA-155 expression in human breast cancer. J Surg Oncol. 2011; 106(3):260-6. DOI: 10.1002/jso.22153. View

19.

Feng B, Wang R, Chen L . MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett. 2011; 317(2):184-91. DOI: 10.1016/j.canlet.2011.11.024. View

20.

Vajkoczy P, Knyazev P, Kunkel A, Capelle H, Behrndt S, von Tengg-Kobligk H . Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A. 2006; 103(15):5799-804. PMC: 1458653. DOI: 10.1073/pnas.0510923103. View